Association Between ABO Polymorphism and Gastric/Colorectal Cancers

NCT ID: NCT06149923

Last Updated: 2023-11-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

184 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-12-01

Study Completion Date

2026-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess ABO gene polymorphism (rs8176746) in the patients histopathologically confirmed gastric and/or colorectal cancers relative to healthy controls by real time PCR.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The ABO blood group system was discovered by the Austrian pathologist Karl Landsteiner in 1901, who classified the blood groups based on the presence of A and B antigens on the surface of red blood cells after noting patterns of agglutination during blood transfusion. Since the discovery of the ABO blood group system , several studies investigating the relationship between the ABO blood group system and various diseases have been conducted , cancer included .

First association between ABO blood group and cancer risk was reported in 1953 in The English patients with gastric cancer.

Gastric cancer is one of the most common malignant tumors of the digestive system , worldwide, gastric cancer is still the fourth most common cancer and the second most common cause of cancer death . The development of gastric cancer is caused by the interaction of genetic and environmental factors , ABO blood grouping is one of the most stable genetic factors.

This association is also observed with other gastrointestinal malignancies, including colorectal cancer which considered the third common cancer in both women and men and responsible for approximately 10% of all cancers, and the third most common cause of cancer related mortality for men and fourth for women .

The ABO is also the first blood group system defined at the gene level . SNP is a single nucleotide polymorphism, is a germ line substitution of a single nucleotide at a specific position in the genome that is present in a sufficiently large fraction of considered population , SNP may act as biological markers, as they can relate to the genes that are associated with various complex diseases as heart diseases, diabetes, cancer … etc.

In previous studies , significant association between ABO gene SNP (rs8176746) , H. Pylori infection, gastric and pancreatic cancer were found , as they observed that this gene SNP was associated with decreased risk of these disorders.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Cancer Colo-rectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

cases

Patients that histopathologically confirmed gastric and/or colorectal cancer, males and females.

quantitative Real-time PCR

Intervention Type GENETIC

: quantitative real time PCR using 7500 fast real time PCR (Applied Biosystems

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

quantitative Real-time PCR

: quantitative real time PCR using 7500 fast real time PCR (Applied Biosystems

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients that histopathologically confirmed gastric and/or colorectal cancer.
* males and females.

Exclusion Criteria

* Presence of other haematological , autoimmune disorders or other malignancies.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Wesam Ashraf Soliman Ahmed

doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Wesam Ashraf Soliman

Role: CONTACT

Phone: 01095574120

Email: [email protected]

References

Explore related publications, articles, or registry entries linked to this study.

Groot HE, Villegas Sierra LE, Said MA, Lipsic E, Karper JC, van der Harst P. Genetically Determined ABO Blood Group and its Associations With Health and Disease. Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):830-838. doi: 10.1161/ATVBAHA.119.313658. Epub 2020 Jan 23.

Reference Type BACKGROUND
PMID: 31969017 (View on PubMed)

Rummel SK, Ellsworth RE. The role of the histoblood ABO group in cancer. Future Sci OA. 2016 Mar 15;2(2):FSO107. doi: 10.4155/fsoa-2015-0012. eCollection 2016 Jun.

Reference Type BACKGROUND
PMID: 28031957 (View on PubMed)

Chen Z, Yang SH, Xu H, Li JJ. ABO blood group system and the coronary artery disease: an updated systematic review and meta-analysis. Sci Rep. 2016 Mar 18;6:23250. doi: 10.1038/srep23250.

Reference Type BACKGROUND
PMID: 26988722 (View on PubMed)

Rummel S, Shriver CD, Ellsworth RE. Relationships between the ABO blood group SNP rs505922 and breast cancer phenotypes: a genotype-phenotype correlation study. BMC Med Genet. 2012 May 29;13:41. doi: 10.1186/1471-2350-13-41.

Reference Type BACKGROUND
PMID: 22642827 (View on PubMed)

Zhou Y, Cui JG, Huang F, Zhang A, Li C, Zhao ZC, Li WD, Fu WH. Prognostic Factors for Survival in Node-Negative Gastric Cancer Patients Who Underwent Curative Resection. Scand J Surg. 2017 Sep;106(3):235-240. doi: 10.1177/1457496916677878. Epub 2017 Apr 4.

Reference Type BACKGROUND
PMID: 28376652 (View on PubMed)

Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006 Jan 21;12(3):354-62. doi: 10.3748/wjg.v12.i3.354.

Reference Type BACKGROUND
PMID: 16489633 (View on PubMed)

Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol. 2009;472:467-77. doi: 10.1007/978-1-60327-492-0_23.

Reference Type BACKGROUND
PMID: 19107449 (View on PubMed)

Sano T, Coit DG, Kim HH, Roviello F, Kassab P, Wittekind C, Yamamoto Y, Ohashi Y. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer. 2017 Mar;20(2):217-225. doi: 10.1007/s10120-016-0601-9. Epub 2016 Feb 20.

Reference Type BACKGROUND
PMID: 26897166 (View on PubMed)

Urun Y, Ozdemir NY, Utkan G, Akbulut H, Savas B, Oksuzoglu B, Oztuna DG, Dogan I, Yalcin B, Senler FC, Onur H, Demirkazik A, Zengin N, Icli F. ABO and Rh blood groups and risk of colorectal adenocarcinoma. Asian Pac J Cancer Prev. 2012;13(12):6097-100. doi: 10.7314/apjcp.2012.13.12.6097.

Reference Type BACKGROUND
PMID: 23464411 (View on PubMed)

Nakao M, Matsuo K, Ito H, Shitara K, Hosono S, Watanabe M, Ito S, Sawaki A, Iida S, Sato S, Yatabe Y, Yamao K, Ueda R, Tajima K, Hamajima N, Tanaka H. ABO genotype and the risk of gastric cancer, atrophic gastritis, and Helicobacter pylori infection. Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1665-72. doi: 10.1158/1055-9965.EPI-11-0213. Epub 2011 Jun 15.

Reference Type BACKGROUND
PMID: 21680535 (View on PubMed)

Rizzato C, Campa D, Pezzilli R, Soucek P, Greenhalf W, Capurso G, Talar-Wojnarowska R, Heller A, Jamroziak K, Khaw KT, Key TJ, Bambi F, Landi S, Mohelnikova-Duchonova B, Vodickova L, Buchler MW, Bugert P, Vodicka P, Neoptolemos JP, Werner J, Hoheisel JD, Bauer AS, Giese N, Canzian F. ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium. Oncol Rep. 2013 Apr;29(4):1637-44. doi: 10.3892/or.2013.2285. Epub 2013 Feb 12.

Reference Type BACKGROUND
PMID: 23403949 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ABO in gastric/colorectal canc

Identifier Type: -

Identifier Source: org_study_id